Antidepressant-Associated Insomnia Risk

Antidepressants That Commonly Cause Insomnia

The American Academy of Family Physicians notes that SSRIs (fluoxetine, paroxetine, sertraline, citalopram) commonly cause insomnia, nervousness, and sleep disturbances as typical side effects 1
The American Academy of Family Physicians recommends that bupropion should not be used in patients with insomnia, and the second dose must be given before 3 p.m. to minimize insomnia risk 1
The American Academy of Family Physicians states that desipramine tends to be activating and may reduce apathy but can cause sleep disruption 1

The American Academy of Family Physicians suggests that mirtazapine is potent, well-tolerated, and promotes sleep, appetite, and weight gain 1
The American Academy of Family Physicians recommends dosing of mirtazapine to start at 7.5 mg at bedtime, with a maximum of 30 mg at bedtime 1
The American Academy of Family Physicians notes that nortriptyline tends to be sedating and may be useful in patients with agitated depression and insomnia 1
The American Academy of Family Physicians recommends dosing of nortriptyline to start at 10 mg at bedtime, with a maximum of 40 mg per day given twice daily 1
The American Academy of Family Physicians states that the therapeutic blood level window of nortriptyline is 50-150 ng/mL 1
The American Academy of Sleep Medicine recommends low-dose doxepin (3-6 mg) for insomnia, which has been approved for treatment of insomnia characterized by difficulties maintaining sleep 2
The American Academy of Sleep Medicine notes that doxepin has minimal anticholinergic effects compared to other tricyclics 2

The American Academy of Family Physicians advises against using SSRIs if insomnia is a primary concern, as they commonly cause sleep disturbances 1
The American Academy of Sleep Medicine recommends choosing sedating antidepressants based on anticholinergic burden (lower is better in elderly patients) 2
The American Academy of Sleep Medicine suggests combining pharmacotherapy with Cognitive Behavioral Therapy for Insomnia (CBT-I) when possible, as sleep hygiene alone is not effective for chronic insomnia 2
The American Academy of Family Physicians recommends a full therapeutic trial of at least 4-8 weeks 1
The American Academy of Family Physicians advises discontinuing antidepressants over 10-14 days to limit withdrawal symptoms 1
The American Academy of Sleep Medicine recommends regular follow-up to monitor for side effects and effectiveness 2

The American Academy of Family Physicians recommends starting mirtazapine at 7.5 mg at bedtime for insomnia, and monitoring for early signs of mood destabilization, including decreased need for sleep, increased energy, racing thoughts, or irritability during the first 4-8 weeks, with the strength of evidence supporting the safety of mirtazapine in bipolar patients when used with a mood stabilizer 3
The American family physician guidelines suggest that mirtazapine can be increased to 15 mg maximum if inadequate response is observed at 6 weeks, while continuing to monitor for mood stability every 2-4 weeks during the initial treatment period, with a moderate level of evidence supporting the efficacy of mirtazapine for insomnia 3

When stopping mirtazapine, taper the dose over 10–14 days rather than stopping abruptly to minimize withdrawal effects such as rebound insomnia, increased anxiety, and irritability. This recommendation is based on evidence from the American Family Physician guideline (2002) and reflects a moderate level of evidence for safe discontinuation. 4